Synergism between rViscumin and cisplatin is not dependent on ERCC-1 expression

Publication type:
Journal article
Metadata:
Autoren
  • O Galm
  • U Fabry
  • T Efferth
  • R Osieka
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000179424400019&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.1016/S0304-3835(02)00411-1
Externe Identifier
  • Clarivate Analytics Document Solution ID: 618NP
  • PubMed Identifier: 12359362
ISSN
0304-3835
Ausgabe der Veröffentlichung
1-2
Zeitschrift
CANCER LETTERS
Schlüsselwörter
  • cytotoxicity
  • recombinant mistletoe lectin
  • drug interaction
  • nucleotide excision repair
  • real-time polymerase chain reaction
Artikelnummer
PII S0304-3835(02)00411-1
Paginierung
143 - 151
Datum der Veröffentlichung
2002
Status
Published
Titel
Synergism between rViscumin and cisplatin is not dependent on <i>ERCC-1</i> expression
Sub types
  • Article
Ausgabe der Zeitschrift
187

Data source: Web of Science (Lite)

Other metadata sources:
Autoren
  • Oliver Galm
  • Ursula Fabry
  • Thomas Efferth
  • Rainhardt Osieka
DOI
10.1016/s0304-3835(02)00411-1
ISSN
0304-3835
Ausgabe der Veröffentlichung
1-2
Zeitschrift
Cancer Letters
Sprache
en
Paginierung
143 - 151
Datum der Veröffentlichung
2002
Status
Published
Herausgeber
Elsevier BV
Herausgeber URL
http://dx.doi.org/10.1016/s0304-3835(02)00411-1
Datum der Datenerfassung
2023
Titel
Synergism between rViscumin and cisplatin is not dependent on ERCC-1 expression
Ausgabe der Zeitschrift
187

Data source: Crossref

Abstract
Interactions between recombinant mistletoe lectin (rViscumin) and anticancer drugs were investigated in vitro. rViscumin enhanced the cytotoxic effects of vincristine, mafosfamide, idarubicin and cisplatin in the human leukemia cell lines K562 and KG1a. In human marrow progenitor cells, rViscumin inhibited colony formation and did not exert any protective activity against cisplatin-induced inhibition of clonogenicity. Quantitative real-time reverse transcription polymerase chain reaction analysis revealed that cisplatin treatment of K562 cells resulted in a 1.9-fold increase in mRNA expression of the nucleotide excision repair gene ERCC-1. This upregulation was not prevented when cells were post-incubated with rViscumin. Our study provides evidence that rViscumin is capable of enhancing cytotoxicity of anticancer agents in vitro. This synergism appears to be independent of transcriptional activity of DNA repair relevant genes.
Addresses
  • Medizinische Klinik IV, Universitätsklinikum Aachen, Pauwelstrasse 30, 52074 Aachen, Germany.
Autoren
  • Oliver Galm
  • Ursula Fabry
  • Thomas Efferth
  • Thomas Efferth
  • Rainhardt Osieka
DOI
10.1016/s0304-3835(02)00411-1
eISSN
1872-7980
Externe Identifier
  • PubMed Identifier: 12359362
Open access
false
ISSN
0304-3835
Ausgabe der Veröffentlichung
1-2
Zeitschrift
Cancer letters
Schlüsselwörter
  • Hematopoietic Stem Cells
  • Tumor Cells, Cultured
  • Bone Marrow
  • Humans
  • Cisplatin
  • Endonucleases
  • Proteins
  • DNA-Binding Proteins
  • Plant Proteins
  • RNA, Messenger
  • RNA, Neoplasm
  • Plant Preparations
  • Antineoplastic Agents
  • Adjuvants, Immunologic
  • Reverse Transcriptase Polymerase Chain Reaction
  • Cell Division
  • DNA Repair
  • Up-Regulation
  • Drug Synergism
  • Base Pair Mismatch
  • Toxins, Biological
  • Ribosome Inactivating Proteins, Type 2
Sprache
eng
Medium
Print
Paginierung
143 - 151
Datum der Veröffentlichung
2002
Status
Published
Datum der Datenerfassung
2002
Titel
Synergism between rViscumin and cisplatin is not dependent on ERCC-1 expression.
Sub types
  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Journal Article
Ausgabe der Zeitschrift
187

Data source: Europe PubMed Central

Abstract
Interactions between recombinant mistletoe lectin (rViscumin) and anticancer drugs were investigated in vitro. rViscumin enhanced the cytotoxic effects of vincristine, mafosfamide, idarubicin and cisplatin in the human leukemia cell lines K562 and KG1a. In human marrow progenitor cells, rViscumin inhibited colony formation and did not exert any protective activity against cisplatin-induced inhibition of clonogenicity. Quantitative real-time reverse transcription polymerase chain reaction analysis revealed that cisplatin treatment of K562 cells resulted in a 1.9-fold increase in mRNA expression of the nucleotide excision repair gene ERCC-1. This upregulation was not prevented when cells were post-incubated with rViscumin. Our study provides evidence that rViscumin is capable of enhancing cytotoxicity of anticancer agents in vitro. This synergism appears to be independent of transcriptional activity of DNA repair relevant genes.
Autoren
  • Oliver Galm
  • Ursula Fabry
  • Thomas Efferth
  • Rainhardt Osieka
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/12359362
DOI
10.1016/s0304-3835(02)00411-1
ISSN
0304-3835
Ausgabe der Veröffentlichung
1-2
Zeitschrift
Cancer Lett
Schlüsselwörter
  • Adjuvants, Immunologic
  • Antineoplastic Agents
  • Base Pair Mismatch
  • Bone Marrow
  • Cell Division
  • Cisplatin
  • DNA Repair
  • DNA-Binding Proteins
  • Drug Synergism
  • Endonucleases
  • Hematopoietic Stem Cells
  • Humans
  • Plant Preparations
  • Plant Proteins
  • Proteins
  • RNA, Messenger
  • RNA, Neoplasm
  • Reverse Transcriptase Polymerase Chain Reaction
  • Ribosome Inactivating Proteins, Type 2
  • Toxins, Biological
  • Tumor Cells, Cultured
  • Up-Regulation
Sprache
eng
Country
Ireland
Paginierung
143 - 151
PII
S0304383502004111
Datum der Veröffentlichung
2002
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2003
Titel
Synergism between rViscumin and cisplatin is not dependent on ERCC-1 expression.
Sub types
  • Comparative Study
  • Journal Article
  • Research Support, Non-U.S. Gov't
Ausgabe der Zeitschrift
187

Data source: PubMed

Beziehungen:
Property of

Tools